132MO Zanidatamab (ZW25; Zani) in patients (pts) with previously treated advanced human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC): Asia subgroup analysis of the phase IIb HERIZON-BTC-01 study
Hsin‐Yun Sun(National Taiwan University Hospital), D-Y. Oh(Seoul National University Hospital), Jing Ma(Center for Life Sciences), M.A. Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Jae‐Weon Kim(Seoul National University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Tae-Jin Song(Tianjin Medical University Cancer Institute and Hospital), Yan Qu(Inner Mongolia Academy of Agricultural & Animal Husbandry Sciences), Phillip M. Garfin(Zymeworks (Canada)), Hsiang-Ju Pan(Sir Run Run Shaw Hospital), K. Dong Uk(Pusan National University Hospital), Yu Guan(Weifang People's Hospital), Xiao Wu(Jazz Pharmaceuticals (United States)), Feng Xie(Qingdao University), Y. Bao(BeiGene (China)), H.-M. Chang(Ulsan College), L. Bao(Hubei Cancer Hospital), Hye Jin Choi(Yonsei University), K. Li(Shandong University)
Cited by 0
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Allelic reprogramming of 3D chromatin architecture during early mammalian development
|Nature|2017|559
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417